Centessa Pharmaceuticals Statistics
Share Statistics
Centessa Pharmaceuticals has 133.55M
shares outstanding. The number of shares has increased by 32%
in one year.
| Shares Outstanding | 133.55M |
| Shares Change (YoY) | 32% |
| Shares Change (QoQ) | 0.74% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 886 |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 5.52M, so 4.13% of the outstanding
shares have been sold short.
| Short Interest | 5.52M |
| Short % of Shares Out | 4.13% |
| Short % of Float | 4.86% |
| Short Ratio (days to cover) | 9.86 |
Valuation Ratios
The PE ratio is -8.13 and the forward
PE ratio is -8.76.
Centessa Pharmaceuticals's PEG ratio is
-0.26.
| PE Ratio | -8.13 |
| Forward PE | -8.76 |
| PS Ratio | 0 |
| Forward PS | 4.6 |
| PB Ratio | 4.78 |
| P/FCF Ratio | -13.49 |
| PEG Ratio | -0.26 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Centessa Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.25,
with a Debt / Equity ratio of 0.29.
| Current Ratio | 9.25 |
| Quick Ratio | 9.25 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | -0.53 |
| Debt / FCF | -0.83 |
| Interest Coverage | -19.92 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-3,061,779.22 |
| Employee Count | 77 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2.84M |
| Effective Tax Rate | -1.22% |
Stock Price Statistics
The stock price has increased by 60.96% in the
last 52 weeks. The beta is 1.54, so Centessa Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.54 |
| 52-Week Price Change | 60.96% |
| 50-Day Moving Average | 13.14 |
| 200-Day Moving Average | 15.28 |
| Relative Strength Index (RSI) | 51.87 |
| Average Volume (20 Days) | 921,198 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -201.06M |
| Net Income | -235.76M |
| EBITDA | -221.97M |
| EBIT | -222.92M |
| Earnings Per Share (EPS) | -2.06 |
Full Income StatementBalance Sheet
The company has 383.22M in cash and 117.23M in
debt, giving a net cash position of 266M.
| Cash & Cash Equivalents | 383.22M |
| Total Debt | 117.23M |
| Net Cash | 266M |
| Retained Earnings | -988.7M |
| Total Assets | 527.85M |
| Working Capital | 323.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -142.06M
and capital expenditures -34K, giving a free cash flow of -142.09M.
| Operating Cash Flow | -142.06M |
| Capital Expenditures | -34K |
| Free Cash Flow | -142.09M |
| FCF Per Share | -1.24 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
